ritonavir
-
Nirmatrelvir/ritonavir use reduces risk for long COVID in patients with immunodeficiency, 2025, Gilbert et al
Nirmatrelvir/ritonavir use reduces risk for long COVID in patients with immunodeficiency [Line breaks added] Selected paragraphs Our findings highlight the potential broad benefit of nirmatrelvir/ritonavir in reducing the risk of long COVID among patients with both primary and secondary...- forestglip
- Thread
- long covid nirmatrelvir paxlovid ritonavir
- Replies: 0
- Forum: Long Covid research
-
Efficacy Of SARS–CoV-2 Specific Antiviral Therapy for Enteroviral [ME/CFS], 2025, Chia et al
Efficacy Of SARS–CoV-2 Specific Antiviral Therapy for Enteroviral Myalgic Encephalomyelitis/ChronicFatigue Syndrome John K Chia, David Wang Background Etiology remains elusive for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and no treatment exists. Antivirals had no efficacy...- forestglip
- Thread
- enterovirus me/cfs nirmatrelvir remdesivir ritonavir
- Replies: 1
- Forum: ME/CFS research